References
- Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve. 2005;32(2):140–63.
- Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, Needham DM. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med. 2007;33(11):1876–91.
- Zochodne DW, Bolton CF, Wells GA, Gilbert JJ, Hahn AF, Brown JD, et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain. 1987;110(Pt 4):819–41.
- Tennila A, Salmi T, Pettila V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med. 2000;26(9):1360–3.
- Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: critical illness polyneuropathy and myopathy. Crit Care. 2008;12(6):238.
- Guillouet M, Gueret G, Rannou F, Giroux-Metges MA, Gioux M, Arvieux CC, et al. Tumor necrosis factor-downregulates sodium current in skeletal muscle by protein kinase C activation: involvement in critical illness polyneuromyopathy. Am J Physiol Cell Physiol. 2011;301:1057–63.
- Novak KR, Nardelli P, Cope TC, Filatov G, Glass JD, Khan J, et al. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest. 2009;119(5):1150–8.
- Hao JX, Stohr T, Selve N, Wiesenfeld-Hallin Z, Xu XJ. Lacosamide, a new anti-epileptic, alleviates neuropathic pain-like behaviors in rat models of spinal cord or trigeminal nerve injury. Eur J Pharmacol. 2006;553(1–3):135–40.
- Geis C, Beyreuther BK, Stohr T, Sommer C. Lacosamide has protective disease modifying properties in experimental vincristine neuropathy. Neuropharmacology. 2011;61(4):600–7.
- Bee LA, Dickenson AH. Effects of lacosamide, a novel sodium channel modulator, on dorsal horn neuronal responses in a rat model of neuropathy. Neuropharmacology. 2009;57(4):472–9.
- Sheets PL, Heers C, Stoehr T, Cummins TR. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther. 2008;326(1):89–99.
- Iseri SO, Sener G, Saglam B, Gedik N, Ercan F, Yegen BC. Oxytocin protects against sepsis-induced multiple organ damage: role of neutrophils. J Surg Res. 2005;126(1):73–81.
- Farivar BS, Eiref SD, Leitman IM. Strategies to prevent sepsis-induced intensive care uniteacquired weakness: are there any options? Commentary on “Comparison of melatonin and oxytocin in the prevention of critical illness polyneuropathy in rats with surgically induced sepsis”. J Surg Res. 2013;185:39–42.
- Leitman IM. Modulating the inflammatory response in sepsis. J Surg Res. 2011;171(2):e183–5.
- Erbas O, Ergenoglu AM, Akdemir A, Yeniel AÖ, Taskiran D. Comparison of melatonin and oxytocin in the prevention of critical illness polyneuropathy in rats with experimentallyinduced sepsis. J Surg Res. 2013;183(1):313–20.
- Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73(1):157–69.
- Fang C, Bourdette D, Banker G. Oxidative stress inhibits axonal transport: implications for neurodegenerative diseases. Mol Neurodegener. 2012;7:29.
- Erbas O, Yeniel AO, Akdemir A, Ergenoglu AM, Yilmaz M, Taskiran D, et al. The beneficial effects of levetiracetam on polyneuropathy in the early stage of sepsis in rats: electrophysiological and biochemical evidence. J Invest Surg. 2013;26(6):312–8.
- Beyreuther BK, Geis C, Stohr T, Sommer C. Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology. 2007;52(5):1312–7.